Registry Study of Non-Ischemic Cardiomyopathies Including Dilated, Hypertrophic, Arrhythmogenic, and Other Rare Types in Adults Aged 18 to 80

What this Trial Is About

Researchers are studying cardiomyopathies CMP, a group of heart muscle diseases, through the DZHK TranslatiOnal Registry for CardiomyopatHies DZHK TORCH. This registry collects clinical data and high-quality biological samples from patients to support innovative clinical and molecular research. Since 2014, the registry has enrolled 2,300 patients and found that CMPs are more common in men, with atrial fibrillation frequently occurring across all forms. The study now extends into a second phase, DZHK TORCH-Plus, aiming to broaden patient numbers and deepen insights into different CMP types, including rare forms. The DZHK TORCH-Plus study has four main parts focusing on clinical phenotyping with follow-up and biosampling, genomics, inflammation, and biomarker analysis. It plans to increase the number of participants to 4,340, include more advanced patient assessments, and extend follow-up periods to better assess outcomes. This phase also investigates factors like myocardial inflammation, fibrosis, gender differences, and genetic markers to improve risk assessment and validate new biomarkers, while fostering collaborations with international registries and industry partners. Participants will undergo detailed clinical evaluations, biosampling, and genomic testing along with ongoing follow-ups to monitor health outcomes over time. Researchers will track all-cause mortality over four years as the primary outcome. The registry collects extensive clinical and molecular data to support risk prediction and guide clinical recommendations for cardiomyopathy patients. The study is observational, with no assigned treatments, and involves adults aged 18 to 80 years, continuing until December 2027.

DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies